The GLP-1 trade is becoming a market-share war, not a rising-tide story
Investors still talk about obesity drugs like a category ETF, but the evidence now points to a leadership trade. Eli Lilly is widening the gap with stronger execution, better prescription momentum, and a more threatening pipeline just as Novo Nordisk faces pricing pressure and a weaker growth profile.
The easy version of the GLP-1 story was that demand was so massive everyone would win. That is getting harder to defend. What the market is seeing now looks less like a broad secular lift and more like a competitive shakeout, with LLY pulling ahead on commercial execution and clinical data while NVO
is being pushed into the kind of pricing moves companies make when they are protecting share, not simply harvesting category growth. This week matters because Lilly’s guidance raise and retatrutide data sharpen the contrast at exactly the moment investors should be asking whether the obesity trade still deserves to be treated as a basket.
Start with the simplest evidence: the fundamentals are no longer moving in parallel. LLY is trading at 38.36x earnings, which looks expensive until you put it next to 44.7% revenue growth and 95.6% EPS growth. NVO, by contrast, sits at 9.93x earnings with just 6.4% revenue growth and 1.7% EPS growth. Cheap stocks can be attractive, but in this case the valuation gap is not the market missing a bargain; it is the market assigning a premium to the company that is actually widening its lead.
The commercial picture makes the divergence even clearer. Lilly reported Q1 revenue of $19.8 billion, up 56% year over year, and then raised full-year 2026 guidance to $82.0 billion to $85.0 billion in revenue with non-GAAP EPS of $35.50 to $37.00. That is what category leadership looks like: volume growth strong enough to offset lower realized prices and still support a higher outlook. Novo’s setup is the opposite. It warned 2026 sales and profits could fall as much as 13%, described pricing pressure as unprecedented, and later moved to cut Wegovy and Ozempic list prices by as much as 50% to $675 a month starting in January 2027. Investors keep framing obesity drugs as a giant market opportunity, but giant markets do not prevent brutal share fights when one player has better momentum.
Prescription trends are where the rising-tide argument really starts to crack. Recent market data showed Wegovy injection new prescriptions down 10% and total prescriptions down 12%, while Zepbound new prescriptions rose 1% and total prescriptions rose 7%. That is not just demand expanding across the board. That is share moving. Reuters also noted Lilly had already overtaken Novo as the market leader in obesity drugs, and once leadership changes in a therapeutic category, it rarely stays a neat two-player split for long. The company with better efficacy, better supply, and better physician confidence tends to get a disproportionate share of the next wave.
Lilly’s pipeline is what makes this more than a one-quarter commercial win. Retatrutide delivered 28.3% mean weight loss at 80 weeks in TRIUMPH-1, with the highest dose reaching 30.3% at 104 weeks in the extension. That matters because the market is no longer debating whether GLP-1s work; it is debating who can keep raising the efficacy bar while broadening indications and sustaining adherence. If Zepbound is already taking share and retatrutide is setting up as the next bar-raiser, then LLY is not merely benefiting from the category. It is shaping the category’s pecking order.
Yes, bulls can still argue the market is large enough to support multiple winners, and there is some truth there. Lower prices, direct-to-consumer channels, oral formulations, and new indications could expand access materially from here. But that argument increasingly confuses end-market size with equity-market outcomes. Plenty of huge markets end up concentrating profits in one or two leaders, and the obesity space is starting to look like one of them.
That is also why the smaller and later entrants should be treated as optionality, not proof that the whole field wins together. AMGN has a credible obesity program, but its stock is still anchored by a broader business growing revenue 9.9% with a 20.9% net margin. PFE is pushing deeper into obesity development, yet its current numbers still show revenue down 1.6% and net margin at 11.8%. VKTX remains a pure pipeline bet with no sales base and a negative earnings profile. Those names may matter later, but today they do not weaken the case that the investable GLP-1 trade is narrowing around the company with the strongest current execution and the most compelling next-gen data.
A quick snapshot of how the market is already separating the field:
LLY: 38.36x P/E, 44.7% revenue growth, 35.0% net margin
The TickerSpark Score framing should follow that same logic. A category can be structurally attractive while still becoming a bad place to own the laggards. The market is telling investors that LLY deserves leadership status because it has both the numbers and the pipeline to defend it. It is also telling them that NVO is no longer being valued as an untouchable co-leader, but as a company that now has to prove it can stabilize share and pricing in a more competitive market.
The mistake now is to keep treating GLP-1s like a broad thematic allocation where every obesity-linked name rises with demand. We think that framing is stale. The better read is that this has become a market-share war, and in market-share wars the leader usually captures more of the upside than investors expect while the runner-up absorbs more of the pricing pain than bulls want to admit.
What would change our mind? A real stabilization in Novo prescription trends, evidence that price cuts are expanding the pool rather than defending a shrinking slice of it, or credible late-stage data from challengers that materially reset the efficacy or convenience race. Until then, the GLP-1 trade looks less like a secular basket and more like a concentrated leadership story with LLY at the center.
Our take, not advice. This is opinion commentary — informational only, not personalized investment recommendations. Markets carry risk. Do your own research and consider your own situation before any trade.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
